Baxter Ends Cephalosporin Production At Round Lake Plant, Giving Up $30 Million Of 2026 Operating Income
The CFO says the 2027 hit won't simply mirror the lost profit, and the exit also eases issues in a recent FDA warning letter.
Baxter International, the hospital-products maker, will stop making cephalosporin drugs at its Round Lake, Illinois, injectables plant, CEO Andrew Hider said on the company's third-quarter earnings call Thursday. The products are expected to contribute about $50 million in sales and $30 million in operating income in 2026, according to CFO John Rogers.
A plant narrowed to one product family
Production of the cephalosporin products ends at the end of October, Rogers said on the call, though Baxter will keep supporting customers under contract into 2027. Hider said the company is repositioning Round Lake exclusively for non-cephalosporin output and does not expect the exit to create a market shortage.
Hider also said the move helps address some of the issues cited in a recent FDA warning letter, which followed an inspection of the Round Lake facility earlier this year. Baxter booked $39 million in restructuring costs tied to the Round Lake actions in the quarter; Rogers said they are excluded from adjusted earnings.
Injectables sales fell 3% in the quarter, which Rogers attributed to price deflation and manufacturing challenges at Round Lake.
Why 2027 is not a straight subtraction
A Bank of America analyst asked whether losing the line makes 2027 earnings growth harder. Hider said the decision streamlines the site and reduces complexity, and he acknowledged areas the team is looking to offset.
Pressed on 2027 by a Wells Fargo analyst, Rogers said he would not "necessarily flow all of that through," since inventory roll-through and alternative products would soften the blow. Overall, he said, it will be a net headwind.
He also listed other 2027 factors: inflation, tariffs without this year's refund benefit, the end of Vantiv-related transition services by the end of January 2027, and planned product exits.
The quarter around the exit
Baxter, which also makes infusion systems, IV solutions and hospital beds, reported third-quarter sales of about $3 billion, up 5% on a reported and organic basis, and adjusted earnings of $0.58 a share, down 16% on a higher tax rate. It raised its full-year organic sales growth outlook to 3% to 4% from 2% to 3%, and lifted the low end of its adjusted earnings range to $2.05 to $2.15. Its market value was $13.2 billion in Thursday morning trading.
Free cash flow was $448 million in the quarter. A $600 million cash tender offer retired $864 million of debt.
Baxter will give a comprehensive 2027 outlook, with detailed guidance, on its fourth-quarter call in February.
Sources
- Baxter: Q3 Earnings Snapshot — Associated Press
- Baxter Non-GAAP EPS of $0.58 beats by $0.06, revenue of $2.98B beats by $70M (NYSE:BAX) | Seeking Alpha — seekingalpha.com
- Baxter Reports Third-Quarter 2026 Results – Company Announcement - FT.com — Financial Times
- Baxter: Q3 Earnings Snapshot | 9news.com — Associated Press
- Baxter: Q3 Earnings Snapshot | wusa9.com — Associated Press